Electroacupuncture reduces visceral pain and anxiety associated with inflammatory bowel disease by inhibition of vHPC-to-mPFC pathway.

Researchers have discovered how electroacupuncture (EA) may help people with inflammatory bowel disease (IBD) who suffer from both abdominal pain and anxiety. Using a mouse model of IBD, scientists found that electroacupuncture treatment significantly reduced both visceral pain (deep abdominal discomfort) and anxiety-like behaviors. The study investigated the brain circuits involved in these improvements, specifically looking at connections between two important brain regions: the ventral hippocampus (vHPC) and the medial prefrontal cortex (mPFC). These areas are known to play crucial roles in processing chronic pain and regulating emotions. The researchers found that electroacupuncture works by calming down overactive communication between these two brain regions. When they used special techniques to artificially block this brain pathway, they saw similar benefits to electroacupuncture treatment. Conversely, when they stimulated this pathway, it counteracted the benefits of electroacupuncture. This research is important because many IBD patients experience both physical pain and psychological distress, which can significantly impact quality of life. The findings suggest that electroacupuncture doesn't just mask symptoms but actually modulates specific brain circuits involved in pain perception and emotional regulation. This provides scientific evidence for why acupuncture may be an effective complementary therapy for managing the complex symptoms of IBD. If you're considering acupuncture for IBD-related symptoms, consult with a licensed acupuncturist who has experience treating gastrointestinal conditions.

This preclinical study demonstrates that electroacupuncture (EA) alleviates visceral hyperalgesia and anxiety in TNBS-induced IBD mice through modulation of the ventral hippocampus-to-medial prefrontal cortex (vHPC-to-mPFC) pathway. Researchers utilized immunohistochemistry to quantify c-Fos and neurogranin co-labeled glutamatergic neurons, finding EA significantly decreased activation in both vHPC and mPFC regions. Chemogenetic manipulation validated these findings: selective inhibition of the vHPC-to-mPFC pathway replicated EA's therapeutic effects on mechanical allodynia, visceral hyperalgesia, and anxiety, while activation of this pathway antagonized EA's benefits on anxiety and visceral pain (but not mechanical allodynia). The study employed von Frey filament testing for mechanical sensitivity and behavioral anxiety assessments. Clinical implications suggest EA's efficacy in IBD extends beyond peripheral anti-inflammatory effects to include central neural pathway modulation. This provides mechanistic insight into EA's role in treating comorbid visceral pain and anxiety, supporting its use as an adjunctive therapy for IBD patients presenting with these overlapping symptoms.